[{"id":"334119a2-9fba-4e1d-ae62-61c33c68df62","acronym":"D8510C00001","url":"https://clinicaltrials.gov/study/NCT03946800","created_at":"2021-01-18T19:25:53.667Z","updated_at":"2024-07-02T16:35:30.922Z","phase":"Phase 1","brief_title":"A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid Tumors","source_id_and_acronym":"NCT03946800 - D8510C00001","lead_sponsor":"MedImmune LLC","biomarkers":" TNFA","pipe":"","alterations":" ","tags":["TNFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • MEDI1191"],"overall_status":"Completed","enrollment":" Enrollment 61","initiation":"Initiation: 05/08/2019","start_date":" 05/08/2019","primary_txt":" Primary completion: 08/24/2023","primary_completion_date":" 08/24/2023","study_txt":" Completion: 08/24/2023","study_completion_date":" 08/24/2023","last_update_posted":"2023-10-31"}]